Michael Brownstein

Azevan Pharmaceuticals (United States) — United States

Neuroscience · Life Sciences

81h-index38.0kcitations253works7.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuropeptides and Animal Physiology(46), Neuroendocrine regulation and behavior(44), Receptor Mechanisms and Signaling(29), Hypothalamic control of reproductive hormones(20), Neuroscience and Neuropharmacology Research(18)

Publications252 total

Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article
Molecular Medicine·2025· 26 citedOpen Access
G protein coupled receptor transcripts in human immune cells and platelets
Scientific Data·2024· 2 citedOpen Access
Considerations beyond spine pain: do different co-occurring lower body joint pains differentially influence physical function and quality of life ratings?
BMC Musculoskeletal Disorders·2024· 1 citedOpen Access
The utility of the irritability scale in Huntington's disease patients with evidence of irritability or aggression
Parkinsonism & Related Disorders·2024· 2 cited
Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series
Med·2023· 43 cited
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Frontiers in Immunology·2023· 227 citedOpen Access
A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment
Contemporary Clinical Trials Communications·2023· 5 citedOpen Access
Chapter 1 Prophet of the Inner Life: Kitamura Tōkoku
Amsterdam University Press eBooks·2022
Prophet of the Inner Life:
Amsterdam University Press eBooks·2022
Recurrent ESBL Escherichia coli Urosepsis in a Pediatric Renal Transplant Patient Treated With Antibiotics and Bacteriophage Therapy
The Pediatric Infectious Disease Journal·2022· 15 cited
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease
Journal of Personalized Medicine·2022· 9 citedOpen Access
Oxytocin and Related Peptide Hormones: Candidate Anti-Inflammatory Therapy in Early Stages of Sepsis
Frontiers in Immunology·2022· 33 citedOpen Access
Case Report: successful use of phage therapy in refractory MRSA chronic rhinosinusitis
International Journal of Infectious Diseases·2022· 34 citedOpen Access
Injury Prevention, Safe Training Techniques, Rehabilitation, and Return to Sport in Trail Runners
Arthroscopy Sports Medicine and Rehabilitation·2022· 49 citedOpen Access
Critically Ill Patient with Multidrug-Resistant Acinetobacter baumannii Respiratory Infection Successfully Treated with Intravenous and Nebulized Bacteriophage Therapy
Antimicrobial Agents and Chemotherapy·2021· 58 citedOpen Access
Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child
EMBO Molecular Medicine·2021· 66 citedOpen Access
Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy
Viruses·2021· 81 citedOpen Access
The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study
Psychopharmacology·2021· 34 citedOpen Access
Distal Radius Fractures in Patients Aged 50 Years or Older: Obstacles to Bone Health Analysis and Follow-Up in a Community Setting
Journal of Hand Surgery Global Online·2021· 2 citedOpen Access
Receptors | Vasopressin/Oxytocin Receptor Family
Elsevier eBooks·2021
page 1 of 13Next →

Frequent Co-authors

Miklós Palkovits(10), Éva Mezey(6), Juan M. Saavedra(6), Julius Axelrod(6), Pablo Landgraf(4), Sébastien Pfeffer(4), Mihaela Zavolan(4), Thomas Tuschl(4), Harold Gainer(4), Tom I. Bonner(3), Robert P. Sheridan(3), Alexei A. Aravin(3), Minchen Chien(3), James J. Russo(3), John D. Carpten(3), Jeffrey R. Smith(3), Jesse Roth(3), Joan E. Bailey‐Wilson(3), Jeffrey M. Trent(3), Marcel Tappaz(3)